Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company, announced its financial results for the year ended December 31, 2025, revealing a net loss of $11.6 million, a decrease from the $16.3 million loss reported in 2024. The company raised over $20 million in gross proceeds during 2025, bolstering its cash reserves to $11.9 million, which extends its cash runway into the second quarter of 2027. Significant highlights include the publication of the IT-01 Study manuscript in the Lancet's eBioMedicine journal, showcasing promising results in refractory metastatic cancer patients. The company also reported favorable outcomes in the INVINCIBLE-4 Study, where patients receiving INT230-6 prior to standard care exhibited a higher pathological complete response rate compared to those receiving standard care alone. The company plans to resume patient enrollment in both the INVINCIBLE-3 and INVINCIBLE-4 studies as funding allows, emphasizing its commitment to addressing the unmet medical needs in oncology.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.